Search
tazemetostat (Taxverik)
Indications:
- epithelioid sarcoma*
- refractory follicular lymphoma
* 13% objective response rate in two small cohorts of patients with advanced epithelioid sarcoma
Dosage:
- 800 mg BID with or without food
Tabs: 200 mg
Pharmacokinetics:
- mebolized by CYP3A
- 88% bound to plasma proteins
- volume of distribution 1230 L
- terminal elimation 1/2life is 3.1 hours
- inactive metabolites excreted in urine 15% & feces 79%
Adverse effects:
- pain: musculoskeletal pain & abdominal pain
- nausea, vomiting decreased appetite, constipation
- fatigue
Mechanism of action:
- methyltransferase inhibitor
Notes:
- doxorubicin with 24% response rate in epithelioid sarcoma (FDA approval ~1974)
General
antineoplastic agent (chemotherapeutic agent)
References
- Bankhead C
Thumbs Up From FDA Panel for Sarcoma Drug.
Unanimous vote to approve tazemetostat in epithelioid sarcoma
MedPage Today. Dec 18, 2019
- HIGHLIGHTS OF PRESCRIBING INFORMATION
TAZVERIK (tazemetostat) tablets, for oral use
https://www.tazverik.com/Content/pdf/prescribing-information.pdf